ENvue Medical raises up to $1M secured from Alpha Capital; Series X conversion cut to $0.50

ENvue Medical, Inc.

Entered Secured Promissory Note with Alpha Capital Anstalt for up to $1,000,000; $250,000 initial tranche funded Oct 8, 2026.
Note accrues 10% interest, rising to 18% on default; matures Dec 31, 2026 and lender may extend in 3-month increments to Dec 31, 2028.
Secured by substantially all assets: accounts, inventory, manufacturer deposits, patents, trademarks, copyrights and subsidiary equity.
Series X Preferred conversion price lowered to $0.50/share; holders of at least 70% amended the dilutive-issuance price adjustment terms.
Certificate of Amendment filed with Delaware Secretary of State Oct 12, 2026; CEO Doron Besser signed the report.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.